MedTrace Logo

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis

NCT02814409 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1858

Last updated 2024-06-13

No results posted yet for this study

Summary

The principle research question is: in patients with acute ischaemic stroke eligible for intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as assessed by modified Rankin Scale distribution at day 90?

Conditions

Interventions

DRUG

Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase

IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion

DRUG

Intravenous Tenecteplase

IV Tenecteplase 0.25mg/kg (max 25mg) single bolus

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • University of Edinburgh

    collaborator OTHER

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Keith Muir, MD, FRCP · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-15
Primary Completion
2023-08-31
Completion
2024-01-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02814409 on ClinicalTrials.gov